Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomised, double-blind, crossover trial

Journal of the Neurological Sciences

Volumn 218, Issue 1-2, 2004, Pages 103-108

  Tomassini, Valentina ^a   Pozzilli, Carlo ^a   Onesti, Emanuela ^a   Pasqualetti, Patrizio ^b   Marinelli, Fabiana ^a   Pisani, Angela ^a   Fieschi, Cesare ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

Author keywords

Acetyl L carnitine; Amantadine; Double blind crossover trial; Fatigue; Fatigue Severity Scale; Multiple sclerosis

Indexed keywords

AMANTADINE; LEVACECARNINE;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; INSOMNIA; MULTIPLE SCLEROSIS; NAUSEA; NERVOUSNESS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 0842305087     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2003.11.005     Document Type: Article

References (44)

1. Krupp L.B., Pollina D.A. Mechanisms and management of fatigue in progressive neurological disorders. Curr. Opin. Neurol. 9:1996;456-460.
2. McDonald W.I., Sears T.A. Focal experimental demyelination in the central nervous system. Brain. 93:1970;575-582.
3. Roelcke U., Kappos L., Lechner-Scott J., Brunnschweiler H., Huber S., Ammann W.et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology. 48:1997;1566-1571.
4. Sheean G.L., Murray N.M., Rothwell J.C., Miller D.H., Thompson A.J. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain. 120:1997;299-315.
5. Filippi M., Rocca M.A., Colombo B., Falini A., Codella M., Scotti G.et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. NeuroImage. 15:2002;559-567.
6. Kent-Braun J.A., Sharma K.R., Miller R.G., Weiner M.W. Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis. Muscle Nerve. 17:1994;835-841.
7. Sharma K.R., Kent-Braun J., Mynhier M.A., Weiner M.W., Miller R.G. Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. Muscle Nerve. 18:1995;1403-1411.
8. Kent-Braun J.A., Ng A.V., Castro M., Weiner M.W., Gelinas D., Dudley G.A.et al. Strength, skeletal muscle composition, and enzyme activity in multiple sclerosis. J. Appl. Physiol. 83:1997;1998-2004.
9. Murray T.J. Amantadine therapy for fatigue in multiple sclerosis. Can. J. Neurol. Sci. 12:1985;251-254.
10. Weinshenker B.G., Penman M., Bass B., Ebers G.C., Rice G.P. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology. 42:1992;1468-1471.
11. Polman C.H., Bertelsmann F.W., van Loenen A.C., Koetsier J.C. 4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch. Neurol. 51:1994;292-296.
12. Rossini P.M., Pasqualetti P., Pozzilli C., Grasso M.G., Millefiorini E., Graceffa A.et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult. Scler. 7:2001;354-358.
13. Rammohan K.W., Rosenberg J.H., Lynn D.J., Blumenfeld A.M., Pollak C.P., Nagaraja H.N. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J. Neurol. Neurosurg. Psychiatry. 72:2002;179-183.
14. Zifko U.A., Rupp M., Schwarz S., Zipko H.T., Maida E.M. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J. Neurol. 249:2002;983-987.
15. Krupp L.B., Coyle P.K., Doscher C., Miller A., Cross A.H., Jandorf L.et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 45:1995;1956-1961.
16. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can. J. Neurol. Sci. 14:1987;273-278.
17. Cohen R.A., Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch. Neurol. 46:1989;676-680.
18. Plioplys A.V., Bagherpour S., Kasnicka I. L-Carnitine as a treatment of lethargy in children with chronic neurologic handicaps. Brain Dev. 16:1994;146-149.
19. Plioplys A.V., Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology. 35:1997;16-23.
20. Graziano F., Bisonni R., Catalano V., Silva R., Rovidati S., Mencarini E.et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br. J. Cancer. 86:2002;1854-1857.
21. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C.et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
22. Lublin F.D., Reingold S.C. Guidelines for clinical trials of new therapeutic agents in multiple sclerosis. Neurology. 48:1997;572-574.
23. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 33:1983;1444-1452.
24. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 46:1989;1121-1123.
25. Fisk J.D., Ritvo P.G., Ross L., Haase D.A., Marrie T.J., Schlech W.F. Measuring the functional impact of fatigue: initial validation of the Fatigue Impact Scale. Clin. Infect. Dis. 18(Suppl. 1):1994;S79-S83.
26. Beck A.T., Ward C.H., Medelson M., Mock J.E., Mohr D.C., Erbaugh J.K. An inventory for measuring depression. Arch. Gen. Psychiatry. 4:1961;567-571.
27. Tempelaar R., De Haes J.C., De Ruiter J.H., Bakker D., Van Den Heuvel W.J., Van Nieuwenhuijzen M.G. The social experiences of cancer patients under treatment: a comparative study. Soc. Sci. Med. 29:1989;635-642.
28. Siliprandi N., Siliprandi D., Ciman M. Stimulation of oxidation of mitochondrial fatty acids and of acetate by acetylcarnitine. Biochem. J. 96:1965;777-780.
29. Murray W.J., Reed K.W., Roche E.B. Conformations of carnitine and acetylcarnitine and the relationship to mitochondrial transport of fatty acids. J. Theor. Biol. 82:1980;559-572.
30. Bieber L.L., Krahling J.B., Clarke P.R., Valkner K.J., Tolbert N.E. Carnitine acyltransferases in rat liver peroxisomes. Arch. Biochem. Biophys. 211:1981;599-604.
31. Bieber L.L. Carnitine. Annu. Rev. Biochem. 57:1988;261-283.
32. Dolezal V., Tucek S. Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose for the synthesis of acetylcholine in rat brain slices. J. Neurochem. 36:1981;1323-1330.
33. Falchetto S., Kato G., Provini L. The action of carnitines on cortical neurons. Can. J. Physiol. Pharmacol. 49:1971;1-7.
34. Imperato A., Ramacci M.T., Angelucci L. Acetyl-L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats. Neurosci. Lett. 107:1989;251-255.
35. Perez-Polo J.R., Werrbach-Perez K., Yang R., Angelucci L. Effects of acetylcarnitine on PC12 cells and aged rat hippocampus. Trans. Am. Soc. Neurochem. 19:1988;1.
36. Curti D., Dagani F., Galmozzi M.R., Marzatico F. Effect of aging and acetyl-L-carnitine on energetic and cholinergic metabolism in rat brain regions. Mech. Ageing Dev. 47:1989;39-45.
37. Angelucci L., Ramacci M.T., Taglialatela G., Hulsebosch C., Morgan B., Werrbach-Perez K.et al. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J. Neurosci. Res. 20:1988;491-496.
38. Sershen H., Harsing L.G. Jr., Banay-Schwartz M., Hashim A., Ramacci M.T., Lajtha A. Effect of acetyl-L-carnitine on the dopaminergic system in aging brain. J. Neurosci. Res. 30:1991;555-559.
39. Shug A.L., Schmidt M.J., Golden G.T., Fariello R.G. The distribution and role of carnitine in the mammalian brain. Life Sci. 31:1982;2869-2874.
40. Kuratsune H., Yamaguti K., Lindh G., Evengard B., Hagberg G., Matsumura K.et al. Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. Neuroimage. 17:2002;1256-1265.
41. Kuratsune H., Yamaguti K., Takahashi M., Misaki H., Tagawa S., Kitani T. Acylcarnitine deficiency in chronic fatigue syndrome. Clin. Infect. Dis. 18(Suppl. 1):1994;S2-S7.
42. Kuratsune H., Yamaguti K., Watanabe Y., Takahashi M., Nakamoto I., Machii T.et al. Acylcarnitine and chronic fatigue syndrome. DeSimone C. Carnitine today. 1997;195-213 Landes Bioscience, Austin, TX.
43. Roelcke U., Kappos L., Lechner-Scott J., Brunnschweiler H., Huber S., Ammann W.et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology. 48:1997;1566-1571.
44. Filippi M., Rocca M.A., Colombo B., Falini A., Codella M., Scotti G.et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage. 15:2002;559-567.